Dorzagliatin in the treatment of type 2 diabetes:a rapid health technology assessment
10.12173/j.issn.1005-0698.202412057
- VernacularTitle:多格列艾汀治疗2型糖尿病的快速卫生技术评估
- Author:
Yujie LI
1
;
Wenjing ZHANG
;
Hongxin YANG
;
Hao GUO
Author Information
1. 内蒙古自治区人民医院药学处(呼和浩特 010017);包头医学院药学院(内蒙古包头 014040)
- Publication Type:Journal Article
- Keywords:
Dorzagliatin;
Type 2 diabetes mellitus;
Rapid health technology assessment;
Efficacy;
Safety;
Economy
- From:
Chinese Journal of Pharmacoepidemiology
2025;34(4):448-455
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy,safety and cost-effectiveness of dorzagliatin in the treatment of type 2 diabetes mellitus using a rapid health technology assessment,and to provide medical evidence for clinical decision-making.Methods PubMed,Embase,Cochrane Library,CNKI,Wanfang Data,SinoMed and relevant health technology assessment(HTA)websites and databases were searched to collect systematic reviews/Meta-analysis,pharmacoeconomic literature and HTA reports of dorzagliatin in the treatment of type 2 diabetes from inception to July 20,2024.Two reviewers independently screened literature,extracted date and assessed quality.The results were qualitatively described and analyzed.Results A total of 6 studies were included,including 5 systematic reviews/Meta-analysis and a pharmacoeconomic study.In terms of efficacy compared with placebo,dorzagliatin significantly reduced glycated hemoglobin(HbA1c),fasting plasma glucose,2-hour postprandial blood glucose and insulin resistance index(P＜0.05),improved HbA1c compliance rate in terms of safety,dorzagliatin,and enhanced homeostasis model assessment-β(P＜0.05),significantly increased total cholesterol,triglyceride,body weight and body mass index(P＜0.05).In terms of safety,the total incidence of adverse reactions of dorzagliatin was slightly higher than that of the placebo group(P＜0.05).However,there was no significant difference in the incidence of severe adverse reactions between the two groups(P＞0.05),and there was no significant increase in the incidence of hyperlipidemia and hypoglycemia(P＞0.05).In terms of economy,the treatment of dorzagliatin combined with metformin has a long-term cost-utility advantage,with an economic probability of nearly 70％.Conclusion Compared with placebo,dorzagliatin has a good overall efficacy and safety in the treatment of type 2 diabetes.In terms of safety,the total incidence of adverse reactions of dorzagliatin was slightly higher than that of placebo.In terms of economy,compared with metformin alone,dorzagliatin combined with metformin has economic advantages.However,there is a lack of head-to-head comparisons of doxorubicin with other classes of glucose-lowering medications,and none of the included studies described long-term cardiac,cerebral,or renal benefits,which limits the comprehensive evaluation of the efficacy and safety of dorzagliatin.
